Resource Summary Report

Generated by dkNET on Sep 7, 2026

MV4-11

RRID:CVCL_0064
Type: Cell Line

Proper Citation

RRID:CVCL_0064

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0064

Proper Citation: RRID:CVCL_0064

Description: Cell line MV4-11 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Childhood acute monocytic leukemia

Defining Citation: PMID:1423625, PMID:2656885, PMID:3496132, PMID:8353274, PMID:8358709, PMID:9195772, PMID:12529668, PMID:14504097, PMID:14671638, PMID:15843827, PMID:16408098, PMID:19608861, PMID:20215515, PMID:20922763, PMID:21552520, PMID:22460905, PMID:25485619, PMID:25877200, PMID:25984343, PMID:26589293, PMID:27397505, PMID:30285677, PMID:30629668, PMID:30894373, PMID:31068700, PMID:35839778, PMID:36982453

Comments: Karyotypic information: 48,XY,t(4;11)(q21;q23),+8,+19 (ATCC=CRL-9591)., Characteristics: CSF2 and IL3 dependent., Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MV4-11

Synonyms: MV-4-11, MV-4:11, MV4:11, MV 4;11, MV4;11, MV411, MV(4;11), MV4II

Cross References: BTO:BTO_0006413, CLO:CLO_0007906, EFO:EFO_0002242, CLDB:cl3610, CLDB:cl3611, AddexBio:C0003025/4955, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610,

ATCC:CRL-9591, ATCC:HTB-189, BioGRID_ORCS_Cell_line:138, BioSample:SAMN01821582, BioSample:SAMN01821649, BioSample:SAMN03473104, BioSample:SAMN10988366, cancercelllines:CVCL_0064, CCRID:3101HUMSCSP5031, Cell_Model_Passport:SIDM00657, ChEMBL-Cells:CHEMBL3308063, ChEMBL-Targets:CHEMBL613835, CLS:300295, Cosmic:787416, Cosmic:798673, Cosmic:908156, Cosmic:975284, Cosmic:994182, Cosmic:996315, Cosmic:1012104, Cosmic:1037736, Cosmic:1078732, Cosmic:1089516, Cosmic:1127256, Cosmic:1150899, Cosmic:1152712, Cosmic:1181603, Cosmic:1278781, Cosmic:1281340, Cosmic:1308221, Cosmic:1319550, Cosmic:1451846, Cosmic:1476424, Cosmic:1516631, Cosmic:1524837, Cosmic:1623635, Cosmic:1696137, Cosmic:1779133, Cosmic:2131568, Cosmic:2306226, Cosmic:2392908, Cosmic:2393011, Cosmic:2542841, Cosmic:2750867, Cosmic-CLP:908156, DepMap:ACH-000045, DSMZ:ACC-102, DSMZCellDive:ACC-102, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, FANTOM5_SSTAR:10718-109I7, GDSC:908156, GEO:GSM236796, GEO:GSM236832, GEO:GSM482560, GEO:GSM887344, GEO:GSM888420, GEO:GSM1374694, GEO:GSM1446746, GEO:GSM1670137, IARC_TP53:21521, IGRhCellID:MV4II, LiGeA:CCLE_055, LINCS_LDP:LCL-1092, Lonza:996, PharmacoDB:MV411_972_2019, PRIDE:PXD030304, Progenetix:CVCL_0064, PubChem_Cell_line:CVCL_0064, TOKU-E:2536, Ubigene:YC-C060, Wikidata:Q54907109

ID: CVCL_0064

Record Creation Time: 20220427T220828+0000

Record Last Update: 20260905T181223+0000

Ratings and Alerts

No rating or validation information has been found for MV4-11.

Warning: Discontinued: ATCC; HTB-189
Karyotypic information: 48,XY,t(4;11)(q21;q23),+8,+19 (ATCC=CRL-9591)., Characteristics: CSF2 and IL3 dependent., Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 496 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Eriksson J, et al. (2026) Single-Cell Lineage Tracing Uncovers Resistance Signatures and Sensitizing Strategies to FLT3 Inhibitors in Acute Myeloid Leukemia. Cancer research, 86(7), 1724.

Zhang H, et al. (2026) A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRP?-Independent Mechanism. Molecular cancer therapeutics, 25(1), 21.

Wu S, et al. (2026) Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine. Molecular oncology, 20(2), 555.

Lewis AC, et al. (2026) Inhibition of heme biosynthesis triggers cuproptosis in acute myeloid leukemia. Cell, 189(1), 215.

Zhao S, et al. (2026) RNF25 confers mRNA damage tolerance by curbing activation of the integrated stress response. Molecular cell, 86(7), 1275.

Schäfer S, et al. (2026) ACSL4-associated lipid metabolism is a distinct therapeutic vulnerability in KMT2A-rearranged acute myeloid leukemia. Cell reports, 45(3), 117010.

Peng M, et al. (2026) MMRN1-EGFR drives sialylglycan-Siglec immune evasion in AML leukemia stem cells. Cell stem cell, 33(5), 800.

Chen TQ, et al. (2026) RBM15B recognizes H3K79me2 to guide selective m6A-modification of mRNA and enhance oncoprotein translation in MLL-r leukemia. The EMBO journal, 45(5), 1672.

Zwick M, et al. (2026) FLT3-ITD Induces CMTM6 and Enhances Immune Escape in Acute Myeloid Leukemia. Cancer research, 86(2), 367.

Saad J, et al. (2026) Predictors of response and rational combinations for the novel MCL-1 inhibitor MIK665 in acute myeloid leukemia. Molecular oncology, 20(2), 389.

Chen Y, et al. (2026) DualPG-DTA: A Large Language Model-Powered Graph Neural Network Framework for Enhanced Drug-Target Affinity Prediction and Discovery of Novel CDK9 Inhibitors Exhibiting In Vivo Anti-Leukemia Activity. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(12), e13099.

Yagüe-Capilla M, et al. (2026) IMPDH inhibition enhances cytarabine efficacy in SAMHD1-expressing leukaemia cells via guanine nucleotide depletion. Molecular oncology.

Sun X, et al. (2026) Targeting UGCG sensitizes AML cells to venetoclax through RAB32-mediated endoplasmic reticulum-mitochondria communication. Cell reports, 45(3), 117021.

He C, et al. (2026) Biomimetic Copper-Doped Nano-Aluminum Adjuvant Potentiates Therapy in Chemoresistant Acute Myeloid Leukemia. Advanced healthcare materials, 15(19), e04039.

Chung J, et al. (2026) Sialylated CD43 forms a glyco-immune barrier that restrains antileukemic immunity. Science (New York, N.Y.), 392(6794), eady5196.

Jin K, et al. (2026) LDLRAD2 drives glycolysis and angiogenesis to promote extramedullary infiltration in acute myeloid leukemia. iScience, 29(6), 115987.

Waclawiczek A, et al. (2026) Leukemic stem cell subtypes determine venetoclax resistance and therapeutic vulnerabilities in AML. Cell stem cell, 33(6), 982.

Dong G, et al. (2026) Discovery of SKP2-Recruiting PROTACs for Target Protein Degradation. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(20), e15159.

Liu Y, et al. (2026) Integrated scFv identification and CAR T cell generation for AML targeting in vivo. International journal of cancer, 158(4), 994.

Uible EE, et al. (2026) Scaffolding-dependent CASP1 constrains excessive cell-intrinsic inflammatory signaling in leukemia. Cell chemical biology, 33(1), 59.